Protagonist Therapeutics (PTGX) Change in Account Payables (2015 - 2026)

Protagonist Therapeutics has disclosed Change in Account Payables across 12 years of filings, most recently posting $3.0 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $3.0 million, up 142.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 million (up 835.79% YoY), and the FY2025 annual result was $3.7 million, up 342.16% from the prior year.
• Change in Account Payables came in at $3.0 million for Q1 2026 at Protagonist Therapeutics, up from -$307000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $5.6 million in Q1 2022 to a low of -$5.7 million in Q2 2022.
• The 5-year median for Change in Account Payables is $375000.0 (2025), against an average of $396764.7.
• Across the five-year window, Change in Account Payables slumped 369.11% in 2023 and jumped 781.13% in 2025, its largest moves.
• Protagonist Therapeutics' Change in Account Payables stood at $2.9 million in 2022, then slumped by 120.5% to -$597000.0 in 2023, then plunged by 139.53% to -$1.4 million in 2024, then jumped by 78.53% to -$307000.0 in 2025, then soared by 1078.18% to $3.0 million in 2026.
• The last three Change in Account Payables figures came in at $3.0 million (Q1 2026), -$307000.0 (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.